Pharmacotherapy in the critically ill obese patient

Critical Care Clinics

Volumn 26, Issue 4, 2010, Pages 679-688

  Medico, Charles J ^a,b   Walsh, Patrick ^a,c  

^a GEISINGER MEDICAL CENTER   (United States)

^b WILKES UNIVERSITY   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Body weight; Dosing; Obese; Pharmacotherapy

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ARGATROBAN; BENZODIAZEPINE; CARBAPENEM; CEFAZOLIN; CEFOTAXIME; CEPHALOSPORIN; CIPROFLOXACIN; DAPTOMYCIN; DIAZEPAM; DROTRECOGIN; ENOXAPARIN; ERTAPENEM; HEPARIN; LINEZOLID; LORAZEPAM; MIDAZOLAM; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PROPOFOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEDATIVE AGENT; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; BODY MASS; BODY WEIGHT; BOOK; CELLULITIS; CLINICAL TRIAL; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EMBOLISM PREVENTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; NEPHROTOXICITY; NONHUMAN; OBESITY; OTOTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 77958096619     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.07.003     Document Type: Review

References (52)

1. Cheymol G. Clinical pharmacokinetics of drugs in obesity: an update. Clin Pharm 1993, 25:103-114.
2. Salazar D.E., Corcoran G.B. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988, 84:1053-1060.
3. Stockholm K.H., Brochner-Mortensen J., Hoilund-Carlson P.F. Increased glomerular filtration rate and adrenocortical function in obese women. Int J Obes 1980, 4:57-63.
4. Abernethy D.R., Greenblatt D.J. Pharmacokinetics of drugs in obesity. Clin Pharm 1982, 7:108-124.
5. Blouin R.A., Kolpek J.H., Man H.J. Influence of obesity on drug disposition. Clin Pharm 1987, 6:706-714.
6. Weant K.A., Armistead J.A., Ladha A.M., et al. Cost effectiveness of a clinical pharmacist on a neurosurgical team. Neurosurgery 2009, 65(5):946-950.
7. MacLaren R., Bond C.A. Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarction-related events. Pharmacotherapy 2009, 29(7):761-768.
8. Montazeri M., Cook D. Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med 1994, 22(6):1044-1048.
9. MacLaren R., Bond C., Martin S., et al. Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med 2008, 36(12):3184-3189.
10. Rondina M.T., Wheeler M., Rodgers G.M., et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb Res 2010, 125(3):220-223.
11. Davidson B.L., Büller H.R., Decousus H., et al. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemostasis 2007, 5:1191-1194.
12. Clark N.P. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res 2008, 123:S58-S61.
13. Barba R., Marco J., Martín-Alvarez H., et al. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 2005, 3:856-862.
14. Hirsh J., Bauer K.A., Donati M.B., et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(6):141S-159S.
15. Rowan B., Kuhl D., Lee M., et al. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 2008, 18:162-166.
16. Borkgren-Okonek M., Hart R., Pantano J., et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008, 4:625-631.
17. Simone E., Madan A., Tichansky D., et al. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc 2008, 22:2392-2395.
18. Raschke R.A., Reilly B.M., Guidry J.R., et al. The weight-based heparin dosing nomogram compared with a standard care nomogram. Ann Intern Med 1993, 119:874.
19. Hull R.D., Raskob G.E., Rosenbloom D., et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992, 152:1589-1595.
20. Hull R.D., Raskob G.E., Hirsh J., et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986, 315:1109-1114.
21. Spruill W.J., Wade W.E., Huckaby G., et al. Achievement of anticoagulation by using weight based heparin dosing protocol for obese and non-obese patients. Am J Health Syst Pharm 2001, 15:2143-2146.
22. Ellison M.J., Sawyer W.T., Mills T.C. Calculation of heparin dosage in a morbidly obese woman. Clin Pharm 1989, 8:65-68.
23. Yee W.P., Norton L.L. Optimal weight base for a weight-based heparin dosing protocol. Am J Health Syst Pharm 1998, 55:159-162.
24. Schwiesow S., Wessell A., Steyer T. Use of a modified dosing weight for heparin therapy in a morbidly obese patient. Ann Pharmacother 2005, 39:753-756.
25. Bauer S., Ou N., Dreesman B., et al. Effect of body mass index on bleeding frequency and activated partial thromboplastin time in weight based dosing of unfractionated heparin: a retrospective cohort study. Mayo Clin Proc 2009, 84(12):1073-1078.
26. Anand SS, Yusuf S, Pogue J, et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003, 107:2884-2888.
27. Myzienski A., Lutz M., Smythe M. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature. Pharmacotherapy 2010, 30(3):105e-112e.
28. Miller M.T., Rovito P. An approach to venous thromboembolism prophylaxis in laparoscopic roux-en-y gastric bypass surgery. Obes Surg 2004, 14:731-737.
29. Geerts W., Bergqvist D., Pineo G., et al. Prevention of venous thromboembolism American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(6):381S-453S.
30. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
31. Levy H., Small D., Heiselman D., et al. Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis. Ann Pharmacother 2005, 39:262-267.
32. Argatroban [package insert] 2005, GlaxoSmithKline, Research triangle park, NC.
33. Cox D.S., Kleiman N.S., Boyle D.A., et al. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIb/IIIa receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol 2004, 44:981-990.
34. Hursting M., Jang I. Effect of body mass index on argatroban therapy during percutaneous coronary intervention. J Thromb Thrombolysis 2008, 25:273-279.
35. Rice L., Hursting M., Baillie M., et al. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol 2007, 47:1028-1034.
36. Keegan S., Gallagher E., Ernst N., et al. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected confirmed heparin-induced thrombocytopenia. Ann Pharmacother 2009, 43(1):19-27.
37. Peck C.C., Cross J.T. " Getting the dose right": facts a blueprint and encouragements. Clin Pharmacol Ther 2007, 82:2-14.
38. Yost R.L., Deredorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit 1986, 8:189-194.
39. Forse R.A., Karam B., Burlingham B.T., et al. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989, 106:750-757.
40. Manjunath P.P., Bearden D.T. Antimicrobial dosing consideration in obese patients. Pharmacotherapy 2007, 27(8):1081-1091.
41. Newman D., Scheetz M.H., Oluwadamilola A.A., et al. Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 2007, 41:1734-1739.
42. Tam V.H., McKinnon P.S., Akins R.L., et al. Pharmacodynamics of cefepime in patients with gram-negative infections. J Antimicrob Chemother 2002, 50:425-428.
43. Chen M., Nafziger A.N., Drusano G.L., et al. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 2006, 50(4):1222-1227.
44. Stein G.E., Schooley S.L., Peloquim C.A., et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005, 39:427-432.
45. Andes D., van Ogtrop M.L., Peng J., et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002, 46:3484-3489.
46. Dvorchik B.H., Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese and matched nonobese subjects. J Clin Pharmacol 2005, 45:48-56.
47. Tedesco K.L., Rybak M.J. Daptomycin. Pharmacotherapy 2004, 24:41-57.
48. Manjunath P.P., Norenberg T.A., Anderson T., et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007, 51(8):2741-2747.
49. Allard S., Kinzig M., Boivin G., et al. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 1993, 53:368-373.
50. Caldwell J.B. Intravenous ciprofloxacin dosing in morbidly obese patient. Ann Pharmacother 1994, 28:806.
51. Rybak M., Lomaestro B., Rotschafer J., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society Health-System pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
52. Casati A., Putzu M. Anesthesia in the obese patient: pharmacokinetic considerations. J Clin Anesth 2005, 17:134-145.